Navigation Links
AstraZeneca and Mental Health Research Institute in Australia Announce Collaboration to Improve Early Detection of Alzheimer's Disease
Date:7/16/2009

LONDON, July 16 /PRNewswire-FirstCall/ -- AstraZeneca and The Mental Health Research Institute in Melbourne, Australia, today announced that they have entered into a research collaboration agreement to develop new ways of identifying Alzheimer's disease patients at early stages of the disease.

Researchers aim to find out whether testing cognition at short intervals (every one to three months) over an eighteen-month period will make it possible to identify individuals just at the point at which they are beginning to suffer cognitive decline as a result of Alzheimer's disease.

The study will be conducted in conjunction with The Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), which aims to improve understanding of the causes and diagnosis of Alzheimer's disease, and help develop preventative strategies.

Alzheimer's disease is a degenerative brain disease for which there is currently no definitive diagnostic tool. Doctors rely on their clinical judgment to diagnose the disease once it has become symptomatic, but the pathologic process very likely starts a few years beforehand.

Professor Paul Maruff, from the Mental Health Research Institute says, "When assessing cognitive function in an individual at risk for dementia on the first occasion, it is often difficult to determine whether their performance on cognitive tests has declined from some previously higher level. The repeated application of a set of brief and simple cognitive measures could therefore help to identify accurately the point when the onset of Alzheimer's disease was imminent in individual people. This could ultimately lead to a more personalized approach with more effective treatments being given to the right patients at the right time."

Dr Judith Jaeger, Director of Neuroscience Early Clinical Development at AstraZeneca adds, "We recognize that in a
'/>"/>

SOURCE AstraZeneca
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Abbott and AstraZeneca Extend Relationship to Include Co-Promotion of TRILIPIX(R) (fenofibric acid)
2. Abbott and AstraZeneca Submit New Drug Application to the FDA for CERTRIAD(TM), an Investigational Treatment for Mixed Dyslipidemia
3. AstraZeneca Studies Show Relief of Nighttime Heartburn and Reduction in GERD-Related Sleep Disturbances
4. Verus Pharmaceuticals Announces a Lawsuit Against AstraZeneca AB and Tika Lakemedel AB
5. Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation
6. AstraZeneca, the National Alliance for Hispanic Health and LULAC Join Forces to Promote Needed Heart Health Education in Hispanic Communities
7. AstraZeneca Announces TOPROL-XL(R) (Metoprolol Succinate) is Now Available
8. Ingenuity Systems Announces Multi-Year Deal With AstraZeneca
9. Court Grants AstraZeneca Temporary Restraining Order Against Apotex in PULMICORT RESPULES Patent Litigation
10. FDA Advisory Committee Documents for SEROQUEL XR Available on AstraZeneca Web Site
11. AstraZenecas David Brennan Elected PhRMA Board Chairman

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)... announced that it has become a national sponsor o...profit organizations dedicated to arthritis resear... Delray Beach, FL (Vocus) November 27, 200...any specializing in the marketing and retail distr...nced today that is has become a national sponsor o...
(Date:11/27/2009)...conomic burdens, study predicts , , FRID...le with diabetes in the United States is expected ...icts. , That would bring the total by 2034 to a... 23.7 million today. , , At the same time, the c...the study also warns, rising from an estimated $11...
(Date:11/27/2009)...announced today that Spectrum Health (Grand Rapids...orthopedic templating solution and its TraumaCad E... (PRWEB) November 27, 2009 -- Voyant Health&trade...ds, Michigan) has licensed its TraumaCad Enterpris... Extend workflow solution, to allow its orthopedic...
(Date:11/27/2009)...ers who use medical load cells at the heart of the...ging in technology partner Flintec early in the de...ical manufacturers are calling in Flintec load cel...ensuring that progress will not be constrained by ...technology. , (PRWEB) Nov...
(Date:11/26/2009)...fluseasonuponus,it,smoreimportantthanevertoemployg...illness. ,, "Weneedtobeproactivenotonlytokeepou...esick,"saidEileenFinerty,RN,MS,CIC(certifiedininfe...ndoccupationalhealthatHospitalforSpecialSurgery(HS...neofthelowestinfectionratesofanyhospitalinthecount...
Breaking Medicine News(10 mins):Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 2Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 3Health News:XenaCare Holdings Announces National Sponsorship of the Arthritis Foundation 4Health News:Diabetes Cases Expected to Double in 25 Years 2Health News:Diabetes Cases Expected to Double in 25 Years 3Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 2Health News:Voyant Health Announces: Spectrum Health Licenses TraumaCad Enterprise and TraumaCad Extend 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 2Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 3Health News:Pro-active Manufacturers Save Millions with Advanced Flintec Medical Load Cells 4Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 2Health News:Infection-Control Strategies at Leading Hospital Can be Adapted for Everyday Use 3
...ELPHIA (January 22, 2008) -- Researchers from the ...have used a novel molecular method to identify che...man bitter taste receptors. , The findings, publ...ste in particular. , Identification of bitter t...
...chers in the Department of Medicine and Department...e have discovered that chronic pain can be success... an effort to find a more effective treatment for ...ensory neuron targeting by self-complementary AAV8...
...da, MD (Jan. 18, 2008) The use of regular, long-t...ugs (NSAIDs) reduces the risk associated with colo...Gastroenterology , the official journal of the Ame... at doses that are higher than recommended over a ...
...l, January 22, 2007 An international research tea...de lUniversit de Montral (CHUM), has identified ne...e sclerosis (MS). In the February issue of Nature ... the nervous system that affects approximately 55,...
...dies sense painful stimuli through certain recepto...l organs. Specialized nerve fibers relay these sig... pain becomes conscious. The spinal cord is placed...nd at the Institute of Pharmacology and Toxicology...
...taking Nexavar need to be monitored closely, study...) -- ,A drug that prolongs the lives of patients w... of developing high blood pressure. , Patients ta...logy . , Nexavar is an anti-angiogenesis drug, mea...
Other Medicine News:Health News:Food peptides activate bitter taste receptors 2Health News:Researchers find relief for chronic pain 2Health News:Regular, long-term aspirin use reduces risk of colorectal cancer 2Health News:New therapeutic target for treatment of multiple sclerosis 2Health News:Nature publication on pain research 2Health News:Liver Cancer Drug Raises Blood Pressure 2
(Date:11/25/2009)...Calif.,Nov.25/PRNewswire/-- ChemoCentryx,Inc.,ann...ny,sPROTECT-1(theProspectiveRandomizedOralTherapyE...CX282-B)inpatientswithmoderate-to-severeCrohn,sdis...tyandtolerabilityprofile.Thestudydemonstratedevide...tyasdefinedasa70-pointdecreaseintheCrohn,sDiseaseA...
(Date:11/24/2009)...,Nov.24/PRNewswire-FirstCall/--Endologix,Inc.(Nasd...oraorticdisorders,announcedtodaythatithasfiledamot...nfringementlawsuitbroughtagainstitinOctober2009byC...CourtinIndianapolis,Indiana. ,, Endologixhasreq...sPatentandTrademarkOffice(USPTO)conductsproceeding...
(Date:11/24/2009)...24/PRNewswire-FirstCall/--AnadysPharmaceuticals,In...the21stAnnualPiperJaffrayHealthcareConferenceonTue...onferenceisbeingheldatTheNewYorkPalaceHotel.SteveW...adys,willprovideanoverviewofAnadysanditsclinicalde...atepresentationwillbesimultaneouslywebcastandcanbe...
Breaking Medicine Technology:ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 2ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 3ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 4ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference 5Endologix Files Motion to Discontinue Court Proceedings Related to Alleged Patent Infringement 2Anadys Pharmaceuticals to Present at the Piper Jaffray Healthcare Conference 2AMT Provides Business Update for the Third Quarter 2009 14895 1AMT Provides Business Update for the Third Quarter 2009 14895 2AMT Provides Business Update for the Third Quarter 2009 14895 3AMT Provides Business Update for the Third Quarter 2009 14895 45 exercises can reduce neck shoulder pain of women office workers 10780 15 exercises can reduce neck shoulder pain of women office workers 10780 25 exercises can reduce neck shoulder pain of women office workers 10780 3BioSoteria CEO to Present at Drug Safety Conference 14889 1BioSoteria CEO to Present at Drug Safety Conference 14889 2
...ENEVA, April 20, 2007 /PRNewswire/ -- Addex Pharma...n of a Phase IIa proof of,concept trial with its l...he study achieved its primary objective, the absen...al significance, and,also showed trends towards im...igraine pain at other time points. ADX10059 has,al...
...ATTLE--(BUSINESS WIRE)--Apr 19, 2007 - Gilead Scie...results of its Phase III,AIR-CF2 study evaluating ... patients with cystic fibrosis (CF) who have,pulmo...e study, a,28-day treatment course of aztreonam ly...nhaled or intravenous (IV) antibiotics versus,plac...
Other Medicine Technology:Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 2Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 3Addex Reports Positive Results in Phase IIa Clinical Trial With,ADX10059 in Migraine 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 2Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 3Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 4Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 5Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 6Gilead Announces Presentation of Positive Phase III Data on,Aztreonam Lysine for Inhalation in Patients With Cystic Fibrosis 7
Accucount 1000 (115V/60Hz)
CA-1000 (220V/50Hz)
...gents including linear polyacrylamide gel (LPA), ...d infrared dyes- coupled with online denaturation....raw data, and higher-quality final analyses. All ...equences, filling in the gaps with high-quality se...
ABL555 Blood gas analyzer
Medicine Products: